Scientific breakthrough on objective diagnosis of PTSD
- Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers
- Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD
- Medibio has exclusive worldwide rights to commercialise the technology
SYDNEY, Australia and MINNEAPOLIS, June 26, 2017 (GLOBE NEWSWIRE) -- Australian Stock Exchange-listed medical technology company Medibio Limited (MEB or the Company) announces a new research study, conducted at Emory University, Atlanta GA and funded by Medibio, demonstrates that post-traumatic stress disorder (PTSD) can be accurately diagnosed using a non-invasive protocol involving heart rate data and machine learning algorithms. The research was based on technology developed at Emory University and licensed by Medibio.
The research is described in a paper titled "Classification of post-traumatic stress disorder from heart rate variability metrics with heart rate-based window segmentation," published in the June issue of P hysiological Measurement . Emory researchers Gari Clifford, DPhil, MSc, MA, and Amit Shah, MD, MSCR, achieved an accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD and differentiating them from those without PTSD using 24-hour heart rate data and machine learning algorithms.
The researchers noted that, "O ur results suggest the potential for a non-invasive tool to objectively track PTSD status."
Medibio's collaboration with Emory was announced in January 2017 and is aimed at expanding the use of the technology beyond depression to classifying post-traumatic stress disorder. Under a license agreement, Medibio has the exclusive option and worldwide rights to commercialise new discoveries based on the PTSD diagnostic and monitoring technology developed by Clifford and Shah. The license agreement extends and further solidifies Medibio's intellectual property position and enables the company to service the vast veterans affairs and military clinical markets.
The research was conducted in collaboration with the Department of Veterans Affairs, using its twins database. It is part of a broader ongoing initiative between Emory University and Medibio. A full copy of the paper will be made available on Medibio's website.
Emory's approach used features extracted from quiescent segments, or periods with lowest heart rate (HR), rather than features calculated from the entire 24 hours of ECG heart rate data. The paper states that "Overall, these findings underscore physiologic changes that occur with PTSD, particularly during periods of relative HR quiescence."
The paper concludes that "Our approach of estimating PTSD status from Heart Rate Variability features is non-invasive, automatic, objective, and potentially useful for monitoring progression and/or improvement of a condition". It suggests that "future studies could evaluate if this classifier reflects changes with effective treatment and resolution of PTSD."
"We appreciate the research done by Emory University and our collaboration. The findings from this research provide a significant step forward in assisting veterans by identifying and diagnosing PTSD. This technology will also assist in the direct benefit for screening, diagnosing and treating mental illness among active military service personnel. We look forward to future research and commercial activity in the critical areas of veterans mental health diagnosis and management," said Jack Cosentino, Medibio CEO. "In the United States, over 22 veterans a day commit suicide due to PTSD and mental illness. This technology will change the way care is delivered to millions of people around the world."
PTSD is a chronic disabling psychiatric condition, with prevalence rates of 3.5% in the general US population(1) and 11-30% amongst returning US service members(2). The disorder represents a significant and costly illness to veterans, their families, and society. The US Congressional Budget Office has reported that the annual cost of treating a veteran with PTSD is US$8,300. There are 18.8 million veterans in the US including 2.3 million troops deployed in Iraq and Afghanistan over the past 10 years.
Dr. Gari Clifford, DPhil, MSc, MA, has an international reputation in mHealth and critical care data analysis and the application of signal processing and machine learning to medicine. He joined the faculty at Emory and Georgia Tech in 2014 as an associate professor in the departments of Biomedical Engineering and Bioinformatics, where he is now the interim chair. Previously, as an Associate Professor at the University of Oxford, Dr. Clifford helped found and led one of the five themes at its Sleep & Circadian Neuroscience Institute, where he is now an Honorary Professor. Prior to that, Dr. Clifford was a Principal Research Scientist at MIT, where he managed the collection and dissemination for the world's largest open access hospital database. His research interests focus on machine learning and signal processing for data fusion, prediction and developing confidence intervals and trust metrics. Application areas in health: critical care, mHealth, sleep and circadian rhythms, and resource-constrained environments.
Dr. Amit Shah, MD, MSCR, is an Assistant Professor of Epidemiology with an adjunct appointment in Medicine (Cardiology) at Emory University, and a practicing cardiologist. He is an expert in the study of autonomic function and psychological risk factors for heart disease, and much of his research focuses on understanding the cardiovascular pathophysiology of depression and posttraumatic stress disorder. His training has largely been dedicated to studying the psychophysiology of PTSD, including circadian abnormalities associated with the condition. Recently, his work on PTSD and abnormal circadian rhythm was presented at the American Psychosomatic Society conference.
Disclosure: As inventors and licensees, Drs. Clifford and Shah and Emory University are eligible to benefit financially from this technology. This relationship has been reviewed and is managed by Emory University through its Conflict of Interest office.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF), headquartered in Melbourne, Australia, with US headquarters in Minneapolis, Minnesota, is an evidence-based medical technology company that has developed an objective test to assist in the diagnosis and management of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes a panel of patented (and patent pending) circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental state. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Medibio is listed on the Australian Securities Exchange. and also trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com and www. asx.com.au.
To learn more about Medibio visit www.Medibio.com.au
|Further Information: Website: www.medibio.com.au|
Medibio Shareholder Enquiries:
CEO and Managing Director
T: +1 (952) 465 4787
U.S. Media Enquiries:
T: +1 (212) 532 2208
Australian Media Enquiries:
T: +61 (0) 412 036 231
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Concurrent Stockholders Approve Proposal to Sell Content Delivery & Storage Business to Vecima Networks13.12.2017 22:47 | Pressemelding
ATLANTA , December 13, 2017 - The stockholders of Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation, and delivery of visual media assets, have approved all proposals presented at a special meeting of its stockholders held on December 13, 2017. The proposals related to the sale of Concurrent's content delivery and storage business to Vecima Networks Inc. (TSX:VCM). Derek Elder, President and CEO of Concurrent, commented, "The Board of Directors and our management team appreciate the overwhelming support of our proposals from Concurrent's stockholders. We expect to close the announced transaction with Vecima Networks by the end of the calendar year. The investment committee established by the Board of Directors will continue to evaluate options to maximize the value of the Company's remaining assets after the close of the sale to Vecima." The specific voting results for each of the proposals considered at the special stockholder's
TrueCommerce Announces Integration with AccountMate Business Management Solution13.12.2017 22:14 | Pressemelding
Industry-leading cloud-based EDI solution provides immediate compliance with trading partners and seamless integration with AccountMate PITTSBURGH, Dec. 13, 2017 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, has announced today the availability of integration with AccountMate, one of the market's most flexible ERP systems that is leveraged by over 125,000 users across 200 industries. AccountMate customers now have access to TrueCommerce's global commerce network that provides seamless connectivity and integration with the top 500 North American and European retailers, as well as thousands of other retail outlets, distributors and logistics organizations. "AccountMate is a well-established ERP system provider considered to be one of the world's most flexible accounting and business management software packages," said TrueCommerce president Ross Elliott. "TrueCommerce made a strategic decision t
STEM Designation Granted for SMU Cox Master of Science in Finance13.12.2017 21:46 | Pressemelding
MSF Students Will be Eligible to Apply for STEM OPT Extension Dallas, Texas (SMU), USA, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Beginning in the fall semester of 2018, the SMU Cox Master of Science in Finance degree (MSF) will be STEM-designated. The Board of Trustees of Southern Methodist University in Dallas, Texas, at its December meeting, approved changes to the MS in Finance program curriculum and the request to change the classification of instructional programs (CIP) code. Based on these changes, the SMU Cox MSF program now falls under fields of study considered to be science, technology, engineering and math (STEM). The government of the United States considers expertise in these fields an important driver of innovation and job creation. According to the U.S. Department of Homeland Security, the country is currently facing a shortage of qualified candidates for STEM jobs. As a result, international students completing STEM-designated programs in the U.S. are encouraged to stay
Hitachi Vantara Continues To Bolster Its Global Leadership Team With New Executive Appointments13.12.2017 15:00 | Pressemelding
SANTA CLARA, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced new appointments to its global leadership team: Mark Ablett has been named senior vice president of global go-to-market (GTM) strategy and Daniel Chong has been named senior vice president of Asia Pacific (APAC). Both will report to the company's chief revenue officer, Hans-Peter Klaey. Ablett previously served as Hitachi Vantara's senior vice president (SVP) of APAC, where he helped Hitachi Vantara's APAC theatre to achieve record growth. In his new role, Ablett will be responsible for developing the company's global GTM strategy, partnering with Hitachi Vantara's customers to help them successfully navigate and execute complex digital transformation journeys. Prior to joining Hitachi, Ablett held executive positions with Juniper Networks and SpectraLink, among others. Chong will assume Ablett's former post as SVP of APAC
DTLR Selects ShopperTrak Traffic Insights to Optimize Store Performance13.12.2017 12:11 | Pressemelding
Lifestyle retailer uses ShopperTrak to better understand key metrics and customer insights CHICAGO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyco Retail Solutions today announced that DTLR Inc., a US lifestyle retailer, has selected its ShopperTrak in-store traffic analytics solution, to provide shopper behavior insights across all 107 stores in 12 states and Washington D.C. Following a successful pilot, DTLR deployed the ShopperTrak perimeter analytics solution and related advisory services to position the importance of shopper traffic, conversion, and other key metrics across the organization. ShopperTrak advisory services utilized include store segmentation, peer grouping, goal setting and field-level training to help better understand shopper traffic and how to best leverage the new data insights. "We sought a vendor who could offer perspective on our operational activities and provide tangible ways to optimize in-store performance," said Frank Long, vice president of
Percona Collaborates with AWS on Database Delivery Service13.12.2017 09:02 | Pressemelding
Percona Managed Services to Ensure Customers Running Open Source Databases on AWS Take Optimal Advantage of AWS Resources RALEIGH, N.C., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, announced collaboration with Amazon Web Services (AWS) to serve as an AWS Standard Tier Consulting Partner and Amazon Aurora Service Delivery Partner in the AWS Partner Network (APN). Percona provides managed services to support the use of Amazon Elastic Compute Cloud (Amazon EC2), Amazon Relational Database Service (Amazon RDS), and Amazon Aurora on the flexible, scalable, pay-as-you-go AWS. Percona also announced Percona Monitoring and Management 1.5 with improved support for MySQL on Amazon RDS and Amazon Aurora MySQL. Migrating workloads to AWS can be a vital part of improving customer experience, gaining deeper business insights and increasing efficiency. Whether
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom